174360-08-8

Basic information

• Product Name: Carbamic acid, [2-(methylthio)ethyl]-, 1,1-dimethylethyl ester (9CI)
• Synonyms: Carbamic acid, [2-(methylthio)ethyl]-, 1,1-dimethylethyl ester (9CI);CarbaMic acid, [2-(Methylthio)ethyl]-, 1,1-diMethylethyl ester;tert-Butyl [2-(Methylthio)ethyl]carbaMate, 97%
• CAS NO: 174360-08-8
• Molecular Formula: C₈H₁₇NO₂S
• Molecular Weight: 191.29108
• Product Categories: N-BOC
• Mol File: 174360-08-8.mol

Chemical Properties

• Appearance: Colorless to yellow/Liquid
• Storage Temp.: 2-8°C
• CAS DataBase Reference: Carbamic acid, [2-(methylthio)ethyl]-, 1,1-dimethylethyl ester (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: Carbamic acid, [2-(methylthio)ethyl]-, 1,1-dimethylethyl ester (9CI)(174360-08-8)
• EPA Substance Registry System: Carbamic acid, [2-(methylthio)ethyl]-, 1,1-dimethylethyl ester (9CI)(174360-08-8)

Safety Data

• Hazardous Substances Data: 174360-08-8(Hazardous Substances Data)

Usage

Uses

Used in Chemical Synthesis:
Carbamic acid, [2-(methylthio)ethyl]-, 1,1-dimethylethyl ester (9CI) is used as a reagent in the synthesis of various organic compounds, particularly in the pharmaceutical and agrochemical industries. Its unique structural features allow it to participate in a range of chemical reactions, such as esterification, amidation, and thiol-ene reactions, enabling the creation of diverse molecular structures.
Used in Insecticide Production:
In the agrochemical industry, Carbamic acid, [2-(methylthio)ethyl]-, 1,1-dimethylethyl ester (9CI) is used as a key intermediate in the synthesis of anthranilic diamide insecticides. These insecticides are effective in controlling a wide range of pests, providing protection for crops and contributing to increased agricultural productivity.
Used in Glycopeptidomimetic Synthesis:
In the pharmaceutical industry, Carbamic acid, [2-(methylthio)ethyl]-, 1,1-dimethylethyl ester (9CI) is utilized in the development of new glycopeptidomimetics based on N-substituted oligoglycines bearing N-linked lactoside side chains. These glycopeptidomimetics have potential applications in the treatment of various diseases, including bacterial infections and cancer, due to their ability to target specific biological processes and interact with cellular receptors.

Upstream product

• 67385-09-5 2-[(tert-butoxycarbonyl)amino]-1-ethanethiol 
• 74-88-4 methyl iodide 
• 24424-99-5 di-tert-butyl dicarbonate 
• 18542-42-2 (2-aminoethyl)methylsulfide 
• 96628-67-0 2-(tert-butoxycarbonylamino)ethyl methanesulfonate 
• 5188-07-8 sodium thiomethoxide 
• 34619-03-9 tert-butyldicarbonate 
• 6950-53-4 2‐(methylsulfanyl)ethan‐1‐amine hydrochloride 
• 71999-74-1 tert-butyl N-(2-chloroethyl)carbamate 
• 36016-38-3 tert-Butyl N-hydroxycarbamate 

Downstream Products

• 18542-42-2 (2-aminoethyl)methylsulfide 
• 6950-53-4 2‐(methylsulfanyl)ethan‐1‐amine hydrochloride 
• 21485-78-9 N-methyl-2-(methylthio)ethylamine 

Relevant articles and documents

Novel anthranilic diamide insecticides: Design, synthesis, and insecticidal evaluation

Three series of new anthranilic diamide derivatives containing sulfide, N-cyanomethylsulfilimine, and N-cyanomethylsulfoximine groups were designed and synthesized by coupling the active substructures of anthranilic diamides and sulfoxaflor. The structures of the synthesized compounds were confirmed by infrared spectroscopy, 1H and 13C NMR, and elemental analysis. Several unique structural characteristics were revealed via the crystal structure analysis of compound N-(2-(2-methyl-2-(methylthio)propylcarbamoyl)-4-chloro-6-methylphenyl)-3-bromo-1-(3-chloropyridin-2-yl)-1H-pyrazole-5-carboxamide 16e. Bioassay results indicated that most of the synthesized compounds showed superior insecticidal activities against Mythimna separata and Plutella xylostella when compared with the positive control cyantraniliprole. In particular, N-(2-(2-methyl-2-(N-cyanomethylsulfideimino)propylcarbamoyl)-4-chloro-6-methylphenyl)-3-bromo-1-(3-chloropyridin-2-yl)-1H-pyrazole-5-carboxamide 17e showed excellent insecticidal activity against Mythimna separata, with a mortality rate of 100% at a concentration of 1μgmL-1. These results indicated that sulfide, N-cyanomethylsulfilimine, and N-cyanomethylsulfoximine moieties, as important active substructures, could improve or maintain the activity of the anthranilic diamide and promote novel pesticide development.

SUBSTITUTED PHENYLPROPENYL PYRIDINE DERIVATIVES, THEIR PREPARATION AND PHARMACEUTICAL APPLICATIONS

Disclosed are a substituted phenylpropenylpyridine derivative, a preparation method therefor and the use thereof as a PD-1/PD-L1 inhibitor. In particular, disclosed are a compound of formula (I) or a pharmaceutically acceptable salt, stereoisomer, solvate, or prodrug thereof, a preparation method therefor and the use thereof. The definition of each group in the formula is detailed in the description and claims.

5 - ALA Conjugate preparation method and application thereof

The invention provides 5 - ALA conjugate preparation method and application thereof, and the preparation method comprises 5 - ((2 - aminoethyl) amino) -4 -oxopentanoate synthesis and 5 - ALA conjugate synthesis steps, and the obtained 5 - ALA conjugate is

Base-Mediated Intramolecular Decarboxylative Synthesis of Alkylamines from Alkanoyloxycarbamates

A general and effective method for the synthesis of alkylamine via intramolecular decarboxylation of alkanoyloxycarbamates is described. The alkanoyloxycarbamates are readily prepared with alkyl carboxylic acids and hydroxylamine. The reaction shows a broad range of substrates (primary and secondary alkyl) with functional tolerance, and the corresponding products were obtained in good yields under mild conditions.

A pharmaceutically acceptable salt and its preparation and use

The invention relates to a pharmaceutical salt, and a preparation method and application thereof, in particular to an acid addition salt of N-(4-(3-fluorobenzyl)-3-chlorphenyl)-6-(5-((2-(methylsulfinyl)ethylamino)methyl)-2-furyl)-quinazoline-4-amine shown

N-[ 3-chloro-4 - (3-fluorobenzyloxy) phenyl] - 6 - [5 - [[ 2 - (methyl sulfinyl) ethyl] amino] methyl] - 2-furyl] - 4-quinazolinamine polymorphic and its preparation method

The invention relates to an N-[3-chloro-4-(3-fluorobenzyloxy) phenyl]-6-[5-[[2-(methylenesulfonyl) ethyl] amino] methyl]-2-furanyl]-4-quinazolinamine polymorph and a preparation method thereof, in particular to an N-[3-chloro-4-(3-fluorobenzyloxy) phenyl]

Fused Ring Compound For Use As Mineralocorticoid Receptor Antagonist

The present invention belongs to the technical field of medicine, relating in particular to: a fused ring compound as represented by Formula (I) for use as a mineralocorticoid receptor antagonist, a pharmaceutically acceptable salt thereof, and an isomer thereof; a preparation method for these compounds; a pharmaceutical preparation containing these compounds; and an application of these compounds, the pharmaceutically acceptable salt thereof, or the isomers thereof in the preparation of medicants for the treatment and/or prevention of kidney injury, cardiovascular diseases such as hypertension, and/or endocrine disease. The definitions of X, Y1, Y2, Y3, R1, R2a, R2b, R3a, R3b, R4, Cy and n are as presented in the description.

FUSED RING COMPOUND FOR USE AS MINERALOCORTICOID RECEPTOR ANTAGONIST

The present invention belongs to the technical field of medicine, relating in particular to: a fused ring compound as represented by Formula (I) for use as a mineralocorticoid receptor antagonist, a pharmaceutically acceptable salt thereof, and an isomer thereof; a preparation method for these compounds; a pharmaceutical preparation containing these compounds; and an application of these compounds, the pharmaceutically acceptable salt thereof, or the isomers thereof in the preparation of medicants for the treatment and/or prevention of kidney injury, cardiovascular diseases such as hypertension, and/or endocrine disease. The definitions of X, Y1, Y2, Y3, R1, R2a,R2b , R3a , R3b, R4, Cy and n are as presented in the description.

4-(SUBSTITUTED ANILINO)QUINAZOLINE DERIVATIVES AS TYROSINE KINASE INHIBITORS

The present invention relates to 4-(substituted anilino)-quinazoline derivatives as tyrosine kinase inhibitors. Specifically, compounds of formula I, or pharmaceutically acceptable salts or solvates thereof are disclosed, in which each substitutent in formula I is defined in the description. Preparation method of the compounds of formula I, pharmaceutical compositons and pharmaceutical uses thereof are also disclosed. The compounds of formula I are effective tyrosine kinase inhibitors.

4-(Substituted Anilino)-Quinazoline Derivatives Useful as Tyrosine Kinase Inhibitors

The present invention relates to 4-(substituted anilino)-quinazoline derivatives as tyrosine kinase inhibitors. Specifically, compounds of formula I, or pharmaceutically acceptable salts or solvates thereof are disclosed, in which each substitutent in formula I is defined in the description. Preparation method of the compounds of formula I, pharmaceutical compositions and pharmaceutical uses thereof are also disclosed. The compounds of formula I are effective tyrosine kinase inhibitors.